Related Experiment Videos
Regional fibrosis after intraperitoneal administration of mafosfamide
Abstract:
Mafosfamide is a cyclophosphamide analog which, unlike cyclophosphamide, does not require enzymatic activation and does not cause urinary tract toxicity. Administration of mafosfamide intraperitoneally, but not intravenously, causes a delayed, dose-dependent fibrotic peritoneal reaction associated with an increased incidence of delayed mortality. This phenomenon might complicate interpretation of in vivo laboratory studies of activity and toxicity in which the intraperitoneal route of administration is utilized. Further, this toxic effect presents a problem for the clinical development of this agent for regional therapies such as intraperitoneal installation.
Insights
Mafosfamide, a cyclophosphamide analog, avoids urinary tract toxicity. However, intraperitoneal administration causes peritoneal fibrosis and mortality, complicating its use in regional therapies and lab studies.
Area of Science:
- Oncology
- Pharmacology
- Toxicology
Background:
- Mafosfamide is a cyclophosphamide analog with potential therapeutic advantages.
- Unlike cyclophosphamide, mafosfamide does not require enzymatic activation and lacks urinary tract toxicity.
Purpose of the Study:
- To investigate the toxicological profile of mafosfamide, particularly concerning its administration route.
- To assess the potential complications of mafosfamide's intraperitoneal administration in preclinical studies and clinical development.
Main Methods:
- Comparative analysis of mafosfamide and cyclophosphamide.
- Evaluation of mafosfamide toxicity following intraperitoneal versus intravenous administration in vivo.
- Dose-dependent assessment of fibrotic peritoneal reactions and mortality.
Main Results:
- Intraperitoneal administration of mafosfamide induced a delayed, dose-dependent fibrotic peritoneal reaction.
- This reaction was associated with an increased incidence of delayed mortality.
- Intravenous administration did not produce the same toxic effects.
Conclusions:
- The fibrotic peritoneal reaction following intraperitoneal mafosfamide complicates the interpretation of in vivo studies.
- This toxicity poses a significant challenge for the clinical development of mafosfamide for regional intraperitoneal therapies.